These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34290602)

  • 21. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
    Shu Y; Ding Y; Zhang Q
    Front Oncol; 2022; 12():851522. PubMed ID: 35515123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Li Y; Liang X; Li H; Yang T; Guo S; Chen X
    Front Pharmacol; 2022; 13():906956. PubMed ID: 35928269
    [No Abstract]   [Full Text] [Related]  

  • 25. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
    Yang L; Song X; Zeng W; Zheng Z; Lin W
    Orphanet J Rare Dis; 2023 Oct; 18(1):326. PubMed ID: 37845696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
    Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
    Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
    Jiang Y; Li Y; Wang LXW
    Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
    Çakar E; Oniangue-Ndza C; Schneider RP; Klijn SL; Vogl UM; Rothermundt C; May JR
    Pharmacoecon Open; 2023 Jul; 7(4):567-577. PubMed ID: 36757568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
    Stenehjem D; Lubinga SJ; Wu A; Betts KA
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
    [No Abstract]   [Full Text] [Related]  

  • 31. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
    Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
    J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of nivolumab plus ipilimumab
    Yang L; Cao X; Li N; Zheng B; Liu M; Cai H
    Ther Adv Med Oncol; 2022; 14():17588359221116604. PubMed ID: 35958872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.
    Zhang PF; Shi XQ; Li Q
    Cost Eff Resour Alloc; 2023 Sep; 21(1):65. PubMed ID: 37705023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
    Huo G; Liu W; Kang S; Chen P
    Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.
    Shu Y; Zhang Q; He X; Chen L
    Cancer Manag Res; 2021; 13():8297-8306. PubMed ID: 34764692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
    Zhang C; Liu Y; Tan J; Tian P; Li W
    Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.